Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXERVATE vs IPLEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply,Off-label: Treatment of pressure ulcers, venous stasis ulcers
FDA: Treatment of growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome, GH gene deletion, GH receptor defects) or with neutralizing antibodies to GH.,Off-label: Treatment of insulin-like growth factor-1 deficiency in adults; investigational in ALS and other neurodegenerative disorders.
1 drop in the affected eye(s) twice daily, approximately 6 hours apart.
0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.
Terminal elimination half-life of Cenegermin is approximately 12 hours following topical ocular administration, supporting once-daily dosing
Terminal elimination half-life of 10-12 hours after subcutaneous administration, supporting twice-daily dosing.
Becaplermin is a protein that is expected to be degraded into small peptides and amino acids via general protein catabolism; specific hepatic metabolism is not a significant pathway.
Mecasermin (IGF-1) is metabolized by proteolytic degradation into amino acids; IGFBP-3 is also proteolytically degraded. No significant cytochrome P450 metabolism.
Primarily renal elimination of the active metabolite (Cenegermin) as small peptides and amino acids; unchanged drug excretion is negligible
Renal excretion of intact IGF-I and its metabolites; approximately 70% eliminated via kidneys, with 30% biliary/fecal.
Cenegermin binding to plasma proteins is minimal (<10%) due to its small protein nature
Approximately 90% bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, and a minor fraction to albumin.
Vd not determined for topical ocular route; systemic exposure is low, with Vd estimated less than 0.1 L/kg based on limited systemic absorption
Vd approximately 0.25-0.30 L/kg, indicating distribution primarily to extracellular fluid and well-perfused tissues.
Topical ocular: Systemic bioavailability is negligible (<1%) due to low corneal penetration and extensive proteolysis at the ocular surface
Subcutaneous: Approximately 80-100%.
No dose adjustment required for renal impairment.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30–50 m L/min), reduce dose by 25%; monitor IGF-I closely.
No dose adjustment required for hepatic impairment.
Not studied in hepatic impairment; use with caution in Child-Pugh B or C; consider dose reduction based on clinical response and IGF-I monitoring.
Safety and efficacy in pediatric patients have not been established.
0.5-2 mg/kg subcutaneously once daily, titrated to achieve age-appropriate IGF-I levels.
No specific dose adjustment required; use same dosing as adults.
No specific dose adjustment; initiate at lower end of dosing range (0.5 mg/kg/day) due to potential for decreased renal function and increased sensitivity.
OXERVATE has been associated with an increased risk of mortality from secondary malignancies in patients who have had a malignant neoplasm. The drug should not be used in patients with active malignancy.
Not available (no FDA boxed warning as of current labeling).
Increased risk of malignancy in patients with a history of malignancy; application to ulcers with malignant cells may promote tumor growth; use only on clean, non-infected ulcers; monitor for signs of infection; avoid application to wounds with exposed bone, tendon, or joint capsule.
Hypoglycemia (especially in fasted state), intracranial hypertension, slipped capital femoral epiphysis, lymphatic tissue hypertrophy (e.g., tonsillar/adenoid enlargement), allergic reactions, and progression of pre-existing malignancies. Injection site reactions, lipohypertrophy. Risk of hyperglycemia if used in patients with diabetes. Monitor blood glucose, fundoscopy for papilledema, and for signs of hip/knee pain.
Known hypersensitivity to becaplermin or any product component; active neoplasm at the application site; patients with a history of malignancy (relative contraindication based on black box warning).
Hypersensitivity to mecasermin rinfabate or any component; active or suspected neoplasia; epiphyseal closure (skeletal maturity); children with closed epiphyses (except if indicated for severe IGF-1 deficiency with open epiphyses).
None known; no significant food interactions reported.
No specific food interactions reported. However, to minimize hypoglycemia risk, IPLEX should be administered immediately after a meal or snack. Avoid prolonged fasting. Alcohol use may increase hypoglycemia risk; avoid or limit alcohol consumption.
OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: unknown risk; second and third trimesters: unknown risk.
IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of IGF-1 during organogenesis resulted in fetal growth retardation and increased skeletal abnormalities at doses similar to human exposure. Due to its growth-promoting effects, potential for teratogenicity, and interference with normal fetal development, IPLEX is contraindicated during pregnancy. First trimester: Risk of skeletal and growth abnormalities. Second and third trimesters: continued risk of abnormal fetal growth and development, including organ overgrowth or underdevelopment. Use only if maternal benefits outweigh potential fetal risks; however, generally avoided.
No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; M/P ratio unknown.
It is unknown whether mecasermin rinfabate or its components (IGF-1, IGFBP-3) are excreted in human milk. Due to the potential for serious adverse reactions in the nursing infant, including growth stimulation and hypoglycemia, breast-feeding is not recommended during IPLEX therapy. No M/P ratio is available.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use standard dosing with caution.
No specific pharmacokinetic studies of IPLEX in pregnancy are available. The physiological changes of pregnancy (increased plasma volume, altered renal function, increased hepatic metabolism) may affect clearance of mecasermin rinfabate; however, due to its contraindication, dose adjustments during pregnancy are not recommended. If absolutely necessary, use the lowest effective dose and monitor for efficacy and adverse effects. No established dose adjustment guidelines exist.
OXERVATE (cenegermin-bkbj) is a recombinant human nerve growth factor for neurotrophic keratitis. Administer as one drop in the affected eye(s) six times daily at 2-hour intervals for 8 weeks. Refrigerate at 2-8°C; do not freeze. Protect from light. Discard unused drops after 1 week of first opening. Monitor for corneal epithelial defect closure. Use with caution in patients with active ocular infections or inflammation.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (rh IGF-1) and its binding protein (rh IGFBP-3). It is indicated for growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome) or with GH gene deletion who have developed neutralizing antibodies to GH. Administer subcutaneously; dose is based on IGF-1 levels. Monitor for hypoglycemia, especially after injection; patients should eat shortly after dosing. Do not use in patients with closed epiphyses or active neoplasia. May cause lymphoproliferative disorders; monitor for splenomegaly, lymphadenopathy.
Wash hands before each use.,Instill one drop in the affected eye(s) every 2 hours, 6 times daily.,Refrigerate the medication at all times; do not freeze.,Use within 1 week after opening the vial.,Avoid touching the dropper tip to any surface.,Do not use contact lenses during treatment.,Report any eye pain, redness, or vision changes immediately.,Complete the full 8-week course even if symptoms improve.
Inject IPLEX within 20 minutes after a meal or snack to prevent hypoglycemia.,Rotate injection sites (abdomen, thigh, upper arm) to avoid lipohypertrophy.,Report symptoms of hypoglycemia (shakiness, sweating, confusion) or increased growth velocity.,Keep a log of blood glucose levels if advised by your doctor.,Store IPLEX in the refrigerator (2-8°C); do not freeze. Protect from light.,Do not share needles or pens; dispose of used needles in a sharps container.,Continue regular follow-up appointments for growth monitoring and blood tests.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXERVATE vs IPLEX, answered by our medical review team.
OXERVATE is a Growth Factor (Ophthalmic) that works by OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.. IPLEX is a Growth Factor that works by IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXERVATE and IPLEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXERVATE is: 1 drop in the affected eye(s) twice daily, approximately 6 hours apart.. The standard adult dose of IPLEX is: 0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXERVATE and IPLEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXERVATE is classified as Category C. OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducte. IPLEX is classified as Category C. IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.